TITLE

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

AUTHOR(S)
Juurlink, David N.; Gomes, Tara; Ko, Dennis T.; Szmitko, Paul E.; Austin, Peter C.; Tu, Jack V.; Henry, David A.; Kopp, Alex; Mamdani, Muhammad M.
PUB. DATE
March 2009
SOURCE
CMAJ: Canadian Medical Association Journal;3/31/2009, Vol. 180 Issue 7, p713
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Methods: We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction. The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91- 180 days). Results: Among 13 636 patients prescribed clopidogrel following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls. After extensive multivariable adjustment, current use of proton pump inhibitors was associated with an increased risk of reinfarction (adjusted odds ratio [OR] 1.27, 95% confidence interval [CI] 1.03-1.57). We found no association with more distant exposure to proton pump inhibitors or in multiple sensitivity analyses. In a stratified analysis, pantoprazole, which does not inhibit cytochrome P450 2C19, had no association with readmission for myocardial infarction (adjusted OR 1.02, 95% CI 0.70-1.47). Interpretation: Among patients receiving clopidogrel following acute myocardial infarction, concomitant therapy with proton pump inhibitors other than pantoprazole was associated with a loss of the beneficial effects of clopidogrel and an increased risk of reinfarction.
ACCESSION #
37371380

 

Related Articles

  • Interaction between clopidogrel and proton pump inhibitors: A clinical overview. Nagavi, Jinesh B.; Gurupadayya, B. M. // International Journal of Pharmacy;Jul2014, Vol. 4 Issue 3, p141 

    Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Over recent years there has been much debate about whether some or all proton pump inhibitors might reduce the effectiveness of...

  • DRUG INTERACTIONS WITH DIAZEPAM. Bojanić, Zoran; Bojanić, Novica; Bojanić, Vladmila; Lazović, Marko // Acta Medica Medianae;Jun2011, Vol. 50 Issue 2, p76 

    Diazepam is a benzodiazepine derivative with anxyolitic, anticonvulsant, hypnotic, sedative, skeletal muscle relaxant, antitremor, and amnestic activity. It is metabolized in the liver by the cytochrome P (CYP) 450 enzyme system. Diazepam is N-demethylated by CYP3A4 and CYP2C19 to the active...

  • Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. Binkhorst, L; van Gelder, T; Loos, W J; de Jongh, F E; Hamberg, P; Moghaddam-Helmantel, I M Ghobadi; de Jonge, E; Jager, A; Seynaeve, C; van Schaik, R H N; Verweij, J; Mathijssen, R H J // Clinical Pharmacology & Therapeutics;Jul2012, Vol. 92 Issue 1, p62 

    Tamoxifen undergoes biotransformation into several metabolites, including endoxifen. Differences in metabolism contribute to the interindividual variability in endoxifen concentrations, potentially affecting treatment efficacy. We evaluated the effects of cytochrome P450 (CYP) induction by...

  • Warning over PPI use after an MI. Anekwe, Lilian // Pulse;9/22/2010, Vol. 70 Issue 27, p8 

    The article focuses on the result of the study which shows that proton pump inhibitors prescription to patients with myocardial infarction increases the risk of cardiovascular events.

  • Safety of proton pump inhibitors. Elliott, William T. // Clinical Oncology Alert;Nov2010 Supplement, p1 

    This article focuses on a Danish study which examined the safety of proton pump inhibitors (PPIs) in patients who were hospitalized for myocardial infarction (MI). Results of the study showed that there were similar rates of death or rehospitalization among patients who were discharged on a...

  • Combining PPI and aspirin increases CVD event risk.  // Pulse;6/8/2011, Vol. 71 Issue 21, p9 

    The article reports on the result of the study which suggests that prescribing proton-pump inhibitors to myocardial infarction patients on aspirin can increase their risk of cardiovascular events.

  • Proton Pump Inhibitors and Clopidogrel. Karpman, Harold L. // Internal Medicine Alert;6/29/2011, Vol. 33 Issue 12, p92 

    Proton pump inhibitor use in clopidogreltreated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.

  • Proton pump inhibitors linked to heart attack risk.  // Gastrointestinal Nursing;Jul/Aug2015, Vol. 13 Issue 6, p6 

    The article cites Dr. Andy Lazris, who runs a practice in Columbia, Maryland who disputes a study which show that people who take proton pump inhibitors (PPIs) drugs commonly used for heartburn, are at greater risk of suffering a heart attack.

  • Association with raised risk of myocardial infarction.  // BMJ: British Medical Journal;6/20/2015, Vol. 350 Issue 8013, ph3220 

    The article discusses research published in an issue of "PLoS One" journal which investigated myocardial infarction risk in individuals using proton pump inhibitors.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics